Palvella Therapeutics (PVLA) Director M Sells $935K of Stock

George M. Jenkins, a director at Palvella Therapeutics, Inc. (PVLA), sold 7,174 shares on October 13, 2026. The sale was valued at approximately $935,232, with the shares sold at an average price of $130.36. This transaction is part of a planned selling strategy.

In recent months, Jenkins has shown a pattern of selling shares. Just a day after this transaction, on October 14, he sold another 27,500 shares, which were valued at about $3.58 million. His previous sale on September 15 also involved 27,500 shares, totaling around $4.17 million.

Other Institutional Activity in Palvella Therapeutics

Several institutional investors have also adjusted their positions in Palvella Therapeutics recently. Jennison Associates LLC raised its holdings by 319,993 shares, bringing its total to 960,619 shares worth about $115.8 million. Blackrock Inc. increased its stake by 231,530 shares, now holding 918,357 shares valued at about $110.7 million. Meanwhile, Montanova Capital LLC trimmed its holdings by 18,110 shares, resulting in 1,135,406 shares worth about $136.8 million. First Light Asset Management, LLC also reduced its stake by 208,913 shares, ending with 771,901 shares valued at about $93 million.

Palvella Therapeutics, Inc. Stock Down 6.2%

Palvella Therapeutics shares are currently trading at $119.43, down from a previous close of $150.56. The stock has a 52-week range of $56.55 to $161.38, indicating considerable volatility. The company has struggled recently, with a negative forward P/E ratio of -20.46, reflecting ongoing financial challenges.

Recent Earnings

Palvella Therapeutics' next earnings report is scheduled for November 11, 2026. In its most recent earnings, the company reported an EPS of -$4.85, indicating it has not yet become profitable. The company continues to focus on developing novel therapies for rare genetic skin diseases.

Insider Buying and Selling at Palvella Therapeutics, Inc.

In addition to Jenkins, other insiders have also sold shares. On June 12, 2026, Matthew Korenberg, the CFO and Treasurer, sold 1,000 shares but did not disclose a value. Jenkins has been active in selling shares this fall, indicating a strategic approach to his holdings.

Analysts Set New Price Targets

On October 12, 2026, HC Wainwright & Co. maintained its Buy rating on Palvella Therapeutics with a price target of $246. The following day, William Blair initiated coverage with an Outperform rating. Currently, analysts have a consensus target price of $230.53, suggesting a potential upside from current trading levels.

About Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania. It focuses on developing treatments for serious and rare genetic skin diseases. The company's lead candidate, QTORIN rapamycin, is in advanced clinical trials for various skin conditions.

Bottom Line

As Palvella Therapeutics approaches its next earnings report on November 11, 2026, investors will be watching closely for updates on its clinical trials and market performance. This recent insider activity, especially Jenkins' notable sell-off, adds another layer of interest as the stock continues to navigate a challenging market environment.